StemSight cures severe corneal blindness with an off-the-shelf stem cell therapy - new treatments for blindness by differentiating cell therapies from human pluripotent stem cells.
StemSight has raised €2.8M across 2 funding rounds from 6 investors, most recently a round in Feb 2025. Based in Tampere, Finland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-02-13 | Other | €2.3M | Biothom Oy,Business Finland,Private Investors,Stephen Industries Inc. ,Voima Ventures | View deal → |
| 2021-09-13 | Pre-Seed | €500k | Avohoidon Tutkimussäätiö,Voima Ventures | View deal → |
